-
81por Le Berre, Catherine, Loy, Laura, Lönnfors, Sanna, Avedano, Luisa, Piovani, Daniele“…METHODS: The questionnaire was developed by Philip Morris Products SA in cooperation with European Federation of Crohn's and Ulcerative Colitis Associations. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
82por Higashi, Koki, Koike, Yuhki, Sato, Yuki, Yamashita, Shinji, Nagano, Yuka, Shimura, Tadanobu, Kitajima, Takahito, Matsushita, Kohei, Yokota, Kazuki, Amano, Keishiro, Okugawa, Yoshinaga, Toiyama, Yuji“…Two heated tobacco sticks, called TEREA™ and SENTIA™, were launched in 2021 by Philip Morris International (New York, NY, USA), and their ingestion is associated with a risk of bowel injury because they contain a partially pointed metallic susceptor. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
83por Shah, Neil J, Patel, Vaibhav G, Zhong, Xiaobo, Pina, Luis, Hawley, Jessica E, Lin, Emily, Gartrell, Benjamin A, Febles, Victor Adorno, Wise, David R, Qin, Qian, Mellgard, George, Joshi, Himanshu, Nauseef, Jones T, Green, David A, Vlachostergios, Panagiotis J, Kwon, Daniel H, Huang, Franklin, Liaw, Bobby, Tagawa, Scott, Kantoff, Philip, Morris, Michael J, Oh, William KEnlace del recurso
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
84por Harris, Bradford“…CONCLUSIONS: This study indicates that cigarette designers at Philip Morris, British-American Tobacco, Lorillard and other companies believed for a time that they might be able to reduce some of the most dangerous substances in mainstream smoke through advanced engineering of filter tips. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
85por Ansari, S Michael, Lama, Nicola, Blanc, Nicolas, Bosilkovska, Marija, Donelli, Andrea, Picavet, Patrick, Baker, Gizelle, Haziza, Christelle, Lüdicke, Frank“…BACKGROUND: Tobacco harm reduction, substituting less harmful tobacco products for combustible cigarettes, is a complementary approach for smokers who would otherwise continue to smoke. The Philip Morris International (PMI) Tobacco Heating System (THS) 2.2 is a novel tobacco product with the potential to reduce the risk of harm in smokers compared to continued smoking of combustible cigarettes. …”
Publicado 2018
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
86por Pouly, Sandrine, Ng, Wee Teck, Benzimra, Muriel, Soulan, Alexandre, Blanc, Nicolas, Zanetti, Filippo, Picavet, Patrick, Baker, Gizelle, Haziza, Christelle“…The Tobacco Heating System (THS), developed by Philip Morris International (commercialized as IQOS), is part of the heat-not-burn product category. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
87por Pray, C, Narula, N, Wong, E C, Marshall, J K, Rangarajan, S, Islam, S, Bahonar, A, Alhabib, K F, Kontsevaya, A, Ariffin, F, Co, H U, Al Sharief, W, Szuba, A, Wielgosz, A, Diaz, M L, Yusuf, R, Kruger, L, Soman, B, Li, Y, Wang, C, Yin, L, Erkin, M, Lanas, F, Davletov, K, Rosengren, A, Lopez-Jaramillo, P, Khatib, R, Oguz, A, Iqbal, R, Yeates, K, Avezum, Á, Reinisch, W, Moayyedi, P, Yusuf, S“…Reinisch Consultant of: Speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, Consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, Omass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, Advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC, P. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto